Loading trials...
Searching ClinicalTrials.gov...
We surface recruiting trials from ClinicalTrials.gov with plain-English eligibility guidance. Whether you are HER2+, triple-negative, or post-CDK4/6 inhibitor, knowing your molecular profile determines which trials you qualify for.
Searching ClinicalTrials.gov...
Breast cancer trial eligibility is driven by your tumor's molecular profile. These biomarkers appear most often in eligibility criteria — find them on your pathology report and genomic testing results.
The key biomarkers for breast cancer trial eligibility are: HER2 status (IHC 3+ or FISH+ = HER2-positive; IHC 1+ or 2+/FISH- = HER2-low), hormone receptor status (ER+/PR+), triple-negative status (ER-/PR-/HER2-), BRCA1/BRCA2 germline mutation, PIK3CA mutation, and PD-L1 expression (CPS score).
Ask your oncologist for comprehensive genomic testing — these results directly determine which trials you qualify for.
Yes. HER2-low (IHC 1+ or IHC 2+/FISH-) is a rapidly expanding area. Trastuzumab deruxtecan (Enhertu) is already approved for HER2-low metastatic breast cancer, and multiple Phase 2/3 trials are recruiting for earlier lines, new combinations, and patients who progressed on T-DXd.
Confirm your HER2 IHC score from your pathology report — even 1+ qualifies as HER2-low.
Post-CDK4/6 inhibitor progression is one of the most active areas for breast cancer trials. Options by profile: PIK3CA-mutant → PI3K inhibitor trials (alpelisib combinations); BRCA-mutant → PARP inhibitor trials; ESR1-mutant (get a liquid biopsy) → novel endocrine therapy trials (elacestrant, imlunestrant); HER2-low → ADC trials (T-DXd, datopotamab).
BRCA-mutant patients have strong trial options. Approved agents include olaparib (Lynparza) and talazoparib (Talzenna). Active trials include: PARP inhibitor + immunotherapy combinations, newer PARP inhibitors in earlier lines, and neoadjuvant trials for early-stage BRCA-mutant patients.
Both germline and somatic BRCA mutations may qualify — confirm with your oncologist whether you've had germline genetic testing.
Yes. Trials exist at every stage. After surgery: adjuvant trials test treatments to prevent recurrence. For metastatic patients who had prior surgery, most trials focus on systemic therapy regardless of surgical history.
Upload your surgical and pathology reports — Alongside matches you to trials appropriate for your current disease status and treatment history.
Each trial on ClinicalTrials.gov lists a central contact number and email. Lead with: your diagnosis ("metastatic ER+/HER2- breast cancer"), your biomarker status ("PIK3CA-mutant, post-CDK4/6 inhibitor"), and treatment history.
Alongside provides a word-for-word phone script and email template customized to your profile.
Phase 1 tests safety. Phase 2 tests whether the treatment works. Phase 3 compares the new treatment against the current standard. Most patients look for Phase 2 or 3 trials, where the treatment has shown early promise.
Every trial has a checklist of who can and cannot join. These might include your cancer stage, specific gene mutations, prior treatments, age, and overall health. Meeting these is required — not optional.
No. The experimental treatment in a clinical trial is free. You may still have to pay for routine care like doctor visits, but the trial drug or procedure itself is covered by the sponsor.
Recruiting means the trial is actively looking for participants right now. "Not yet recruiting" means it's approved but hasn't started. "Active, not recruiting" means it's ongoing but has all the participants it needs.